Acorah Software Products - Accounts Production 15.0.400 true true 31 December 2022 1 June 2022 false true No description of principal activity 1 January 2023 31 December 2023 31 December 2023 08085448 Mr Howard Shapland Mr Howard Shapland iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 08085448 2022-12-31 08085448 2023-12-31 08085448 2023-01-01 2023-12-31 08085448 frs-bus:PrivateLimitedCompanyLtd 2023-01-01 2023-12-31 08085448 frs-bus:FilletedAccounts 2023-01-01 2023-12-31 08085448 frs-bus:Micro-entities 2023-01-01 2023-12-31 08085448 frs-bus:EntityHasNeverTraded 2023-01-01 2023-12-31 08085448 frs-bus:AuditExempt-NoAccountantsReport 2023-01-01 2023-12-31 08085448 frs-bus:Director1 2023-01-01 2023-12-31 08085448 frs-bus:CompanySecretary1 2023-01-01 2023-12-31 08085448 2022-05-31 08085448 2022-12-31
Registered number: 08085448
Bioventure Medical Innovations Ltd
Unaudited Financial Statements
For The Year Ended 31 December 2023
GLX Accounting Limited
ICAEW Chartered Accountants
69-75 Thorpe Road
Norwich
NR1 1UA
Balance Sheet
Registered number: 08085448
31 December 2023 31 December 2022
£ £
Current assets 100 100
NET CURRENT ASSETS 100 100
TOTAL ASSETS LESS CURRENT LIABILITIES 100 100
NET ASSETS 100 100
CAPITAL AND RESERVES 100 100

Notes

1. General Information
Bioventure Medical Innovations Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 08085448 . The registered office is C/o GLX, 69-75 Thorpe Road, Norwich, NR1 1UA.
For the year ending 31 December 2023 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.
The member has not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared in accordance with the micro-entity provisions and delivered in accordance with the provisions applicable to companies subject to the small companies' regime.
On behalf of the board
Mr Howard Shapland
Director
5th August 2024